GL Pharm Tech지엘팜텍
204840 · KOSDAQ · ₩204840 · 지엘팜텍
₩3,580▲ ₩5 (0.14%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩35B | ₩26B | ₩26B | ₩17B | ₩12B |
| Cost of sales | ₩21B | ₩16B | ₩17B | ₩12B | ₩8.7B |
| Gross profit | ₩14B | ₩10B | ₩8.7B | ₩4.9B | ₩3.8B |
| Operating income | ₩268M | −₩1.8B | −₩3.2B | −₩3.3B | −₩2.7B |
| Net income | ₩12M | −₩2.3B | −₩3.7B | −₩790M | −₩3.7B |
| Net income to shareholders | ₩12M | −₩2.3B | −₩3.7B | −₩790M | −₩3.7B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩49B | ₩42B | ₩40B | ₩41B | ₩32B |
| Current assets | ₩22B | ₩19B | ₩17B | ₩16B | ₩13B |
| Cash and equivalents | ₩3B | ₩4.3B | ₩4.1B | ₩4.6B | ₩6.2B |
| Total liabilities | ₩29B | ₩23B | ₩28B | ₩25B | ₩14B |
| Current liabilities | ₩21B | ₩14B | ₩12B | ₩13B | ₩4.9B |
| Borrowings | ₩18B | ₩14B | ₩18B | ₩14B | ₩7.7B |
| Total equity | ₩20B | ₩20B | ₩12B | ₩16B | ₩17B |
| Shareholders' equity | ₩20B | ₩20B | ₩12B | ₩16B | ₩17B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩1.1B | −₩4.6B | −₩2.8B | −₩1.3B | −₩2.3B |
| Capital spending | ₩3.2B | ₩392M | ₩579M | ₩6.4B | ₩1.3B |
| Free cash flow | −₩4.3B | −₩5B | −₩3.3B | −₩7.7B | −₩3.6B |
Consolidated where available. Amounts in won.
Also known as: GL Pharm Tech / 지엘팜텍 / 204840 / KRX:204840
Source: KRX statistical information